Drug Profile

FLD 103

Alternative Names: FLD-103

Latest Information Update: 05 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Feldan Therapeutics
Class Antineoplastics; Antisense oligonucleotides; Peptides
Mechanism of Action Zinc finger protein GLI1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Basal cell cancer

Most Recent Events

31 Oct 2024 Phase-I/II clinical trials in Basal cell cancer in Australia (Intralesional) (ACTRN12624001138572)
03 Oct 2023 Feldan Therapeutics plans a first-in-human phase I/II trial in Basal cell cancer (Intralesional) in Q2 of 2024
23 Mar 2023 Preclinical trials in Basal cell cancer in Canada (Intralesional) before March 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com